Ascentage Pharma Group International (NASDAQ:AAPG) Sets New 12-Month Low – Time to Sell?

Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) shares hit a new 52-week low on Thursday . The company traded as low as $15.01 and last traded at $15.03, with a volume of 7363 shares changing hands. The stock had previously closed at $15.58.

Analysts Set New Price Targets

AAPG has been the subject of a number of analyst reports. Raymond James Financial reissued a “buy” rating on shares of Ascentage Pharma Group International in a research note on Wednesday, June 10th. B. Riley Financial initiated coverage on Ascentage Pharma Group International in a report on Wednesday, June 10th. They set a “buy” rating and a $45.00 price objective on the stock. Finally, BTIG Research reiterated a “buy” rating and issued a $48.00 price objective on shares of Ascentage Pharma Group International in a research report on Friday, August 21st. Two equities research analysts have rated the stock with a Strong Buy rating and eight have issued a Buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $46.43.

Ascentage Pharma Group International Stock Down 3.1%

The company’s 50 day moving average is $17.54 and its 200 day moving average is $20.00. The company has a quick ratio of 1.18, a current ratio of 1.22 and a debt-to-equity ratio of 1.09.

Ascentage Pharma Group International (NASDAQ:AAPG) last issued its earnings results on Wednesday, August 19th. The company reported ($0.65) earnings per share for the quarter. The business had revenue of $22.24 million for the quarter. As a group, research analysts anticipate that Ascentage Pharma Group International – Unsponsored ADR will post -2.42 EPS for the current fiscal year.

About Ascentage Pharma Group International

Ascentage Pharma Group International is a biopharmaceutical company focused on discovering and developing therapies that target apoptosis, the natural process of programmed cell death. Its research is directed primarily toward cancer and other serious diseases in which abnormal cell survival contributes to disease progression.

The company’s pipeline includes small-molecule drug candidates designed to inhibit proteins involved in apoptosis regulation, including BCL-2, MDM2 and inhibitor-of-apoptosis proteins.